Cerebrovascular involvement in fabry disease: Current status of knowledge

Stroke

Volumn 46, Issue 1, 2015, Pages 302-313

  Kolodny, Edwin ^a   Fellgiebel, Andreas ^b   Hilz, Max J ^c   Sims, Katherine ^d   Caruso, Paul ^e   Phan, Thanh G ^f   Politei, Juan ^g   Manara, Renzo ^h   Burlina, Alessandro ⁱ  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d Center for Human Genetic Research Neurology Department (KS)   (Germany)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f SOUTHERN HEALTH   (Australia)

^g Department of Neurology Fundacion Para El Estudio de Enfermedades Neurometabolicas ^*  (Argentina)

^h UNIVERSITY OF SALERNO   (Italy)

ⁱ St Bassiano Hospital   (Italy)

Author keywords

basilar artery; Fabry disease; neuroimaging; pulvinar; risk factors; stroke; white matter

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN RECEPTOR; ARYLDIALKYLPHOSPHATASE; BLOOD CLOTTING FACTOR 5 LEIDEN; FATTY ACID BINDING PROTEIN; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; INTERLEUKIN 6; OSTEOCALCIN;

BRAIN ARTERY; BRAIN ISCHEMIA; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR DISEASE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIFFUSION WEIGHTED IMAGING; DYSLIPIDEMIA; EXERCISE; FABRY DISEASE; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE ENVIRONMENT INTERACTION; GENOTYPE PHENOTYPE CORRELATION; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INFARCTION; MAGNETIC RESONANCE ANGIOGRAPHY; OBESITY; ONSET AGE; PATHOPHYSIOLOGY; PREVALENCE; PROTON NUCLEAR MAGNETIC RESONANCE; PULVINAR; REVIEW; RISK FACTOR; SEX; SMOKING; SPINAL CORD INFARCTION; SUBARACHNOID HEMORRHAGE; TRANSIENT ISCHEMIC ATTACK; WHITE MATTER; CEREBROVASCULAR DISORDERS; COMPLICATION; LEUKOENCEPHALOPATHIES; STROKE;

CEREBROVASCULAR DISORDERS; FABRY DISEASE; HUMANS; LEUKOENCEPHALOPATHIES; STROKE;

EID: 84920409668     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.114.006283     Document Type: Review

References (133)

1. Zarate YA, Hopkin RJ. Fabry's disease. Lancet. 2008;372:1427-1435. doi: 10.1016/S0140-6736(08)61589-5.
2. Schiffmann R. Fabry disease. Pharmacol Ther. 2009;122:65-77. doi: 10.1016/j.pharmthera.2009.01.003.
3. Saito S, Ohno K, Sakuraba H. Comparative study of structural changes caused by different substitutions at the same residue on α-galactosidase A. PLoS One. 2013;8:e84267. doi: 10.1371/journal.pone.0084267.
4. Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. doi: 10.1186/1750-1172-5-30.
5. Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 2008;105:2812-2817. doi: 10.1073/pnas.0712309105.
6. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010;99:99-108. doi: 10.1016/j.ymgme.2009.10.004.
7. Namdar M, Gebhard C, Studiger R, Shi Y, Mocharla P, Schmied C, et al. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A defciency causes endothelial dysfunction in Fabry disease. PLoS One. 2012;7:e36373. doi: 10.1371/journal.pone.0036373.
8. Sestito S, Ceravolo F, Concolino D. Anderson-Fabry disease in children. Curr Pharm Des. 2013;19:6037-6045.
9. Hilz MJ, Brys M, Marthol H, Stemper B, Dütsch M. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fbers in Fabry neuropathy. Neurology. 2004;62:1066-1072.
10. Sims K, Politei J, Banikazemi M, Lee P. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009;40:788-794. doi: 10.1161/STROKEAHA.108.526293.
11. Nakamura K, Sekijima Y, Nakamura K, Hattori K, Nagamatsu K, Shimizu Y, et al. Cerebral hemorrhage in Fabry's disease. J Hum Genet. 2010;55:259-261. doi: 10.1038/jhg.2010.18.
12. Chang YH, Hwang SK. A case of cerebral aneurysmal subarachnoid hemorrhage in Fabry's disease. J Korean Neurosurg Soc. 2013;53: 187-189. doi: 10.3340/jkns.2013.53.3.187.
13. Reisin RC, Romero C, Marchesoni C, Nápoli G, Kisinovsky I, Cáceres G, et al. Brain MRI fndings in patients with Fabry disease. J Neurol Sci. 2011;305:41-44. doi: 10.1016/j.jns.2011.03.020.
14. Baptista MV, Ferreira S, Pinho-E-Melo T, Carvalho M, Cruz VT, Carmona C, et al; PORTuguese Young STROKE Investigators. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients. Stroke. 2010;41:431-436. doi: 10.1161/STROKEAHA.109.570499.
15. Brouns R, Thijs V, Eyskens F, Van den Broeck M, Belachew S, Van Broeckhoven C, et al; BeFaS Investigators. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke. 2010;41:863-868. doi: 10.1161/STROKEAHA.110.579409.
16. Putaala J, Kurkinen M, Tarvos V, Salonen O, Kaste M, Tatlisumak T. Silent brain infarcts and leukoaraiosis in young adults with frst-ever ischemic stroke. Neurology. 2009;72:1823-1829. doi: 10.1212/WNL.0b013e3181a711df.
17. Lidove O, Chauveheid MP, Caillaud C, Froissart R, Benoist L, Alamowitch S, et al. Aseptic meningitis and ischaemic stroke in Fabry disease. Int J Clin Pract. 2009;63:1663-1667. doi: 10.1111/j.1742-1241.2009.02115.x.
18. Simoncini C, Orsucci D, Gori S, Giorgi FS, Cosottini M, Siciliano G, et al. Fabry disease with atypical neurological presentation: report of a case. Neurologist. 2012;18:413-414. doi: 10.1097/NRL.0b013e3182761cf6.
19. Schermuly I, Müller MJ, Müller KM, Albrecht J, Keller I, Yakushev I, et al. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol. 2011;18:347-353. doi: 10.1111/j.1468-1331.2010.03155.x.
20. Buechner S, Moretti M, Burlina AP, Cei G, Manara R, Ricci R, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry. 2008;79:1249-1254. doi: 10.1136/jnnp.2008.143693.
21. Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol. 2006;5:791-795. doi: 10.1016/S1474-4422(06)70548-8.
22. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-e245. doi: 10.1161/CIR.0b013e31828124ad.
23. Ginsberg L. Chapter 23. Nervous system manifestations of Fabry disease: data from FOS-the Fabry Outcome Survey. In: Mehta A, Beck M, Sunder-Plassmann G, eds. Fabry Disease: Perspectives From 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006.
24. Grewal RP. Stroke in Fabry's disease. J Neurol. 1994;241:153-156.
25. Moore DF, Scott LT, Gladwin MT, Altarescu G, Kaneski C, Suzuki K, et al. Regional cerebral hyperperfusion and nitric oxide pathway dys-regulation in Fabry disease: reversal by enzyme replacement therapy. Circulation. 2001;104:1506-1512.
26. Gupta S, Ries M, Kotsopoulos S, Schiffmann R. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous women. Medicine (Baltimore). 2005;84:261-268.
27. Vedder AC, Linthorst GE, van Breemen MJ, Groener JE, Bemelman FJ, Strijland A, et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis. 2007;30:68-78. doi: 10.1007/s10545-006-0484-8.
28. Turtzo LC, Siegel C, McCullough LD. X chromosome dosage and the response to cerebral ischemia. J Neurosci. 2011;31:13255-13259. doi: 10.1523/JNEUROSCI.0621-11.2011.
29. Stamova B, Tian Y, Jickling G, Bushnell C, Zhan X, Liu D, et al. The X-chromosome has a different pattern of gene expression in women compared with men with ischemic stroke. Stroke. 2012;43:326-334. doi: 10.1161/STROKEAHA.111.629337.
30. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. J Med Genet. 1996;33:682-688.
31. Germain DP, Echevarria L. Tissue-specifc X chromosome inactivation studies as a decision-making criteria for enzyme replacement therapy in female heterozygotes for Fabry disease. Mol Genet Metab. 2014;111:S45.
32. Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005;366:1794-1796. doi: 10.1016/S0140-6736(05)67635-0.
33. Brouns R, Sheorajpanday R, Braxel E, Eyskens F, Baker R, Hughes D, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg. 2007;109:479-484. doi: 10.1016/j.clineuro.2007.03.008.
34. Wozniak MA, Kittner SJ, Tuhrim S, Cole JW, Stern B, Dobbins M, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with frst ischemic stroke. Stroke. 2010;41:78-81. doi: 10.1161/STROKEAHA.109.558320.
35. Marquardt L, Baker R, Segal H, Burgess AI, Poole D, Hughes DA, et al. Fabry disease in unselected patients with TIA or stroke: population-based study. Eur J Neurol. 2012;19:1427-1432. doi: 10.1111/j.1468-1331.2012.03739.x.
36. Sarikaya H, Yilmaz M, Michael N, Miserez AR, Steinmann B, Baumgartner RW. Zurich Fabry study-prevalence of Fabry disease in young patients with frst cryptogenic ischaemic stroke or TIA. Eur J Neurol. 2012;19:1421-1426. doi: 10.1111/j.1468-1331.2012.03737.x.
37. Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S. Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. J Stroke Cerebrovasc Dis. 2013;22:1288-1292. doi: 10.1016/j. jstrokecerebrovasdis.2012.10.005.
38. Rolfs A, Fazekas F, Grittner U, Dichgans M, Martus P, Holzhausen M, et al; Stroke in Young Fabry Patients (SIFAP) Investigators. Acute cerebro-vascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013;44:340-349. doi: 10.1161/STROKEAHA.112.663708.
39. Lidove O, Joly D, Touzé E. Letter regarding Brouns et al, Baptista et al, and Wozniak et al. Stroke. 2011;42:e4-e5.
40. Linthorst GE, Ginsberg L. Prevalence of Fabry disease in TIA/stroke cohorts. What defnes Fabry disease? Eur J Neurol. 2012;19:1383-1384. doi: 10.1111/j.1468-1331.2012.03763.x.
41. Reuser AJ, Verheijen FW, Bali D, van Diggelen OP, Germain DP, Hwu WL, et al. The use of dried blood spot samples in the diagnosis of lyso-somal storage disorders-current status and perspectives. Mol Genet Metab. 2011;104:144-148. doi: 10.1016/j.ymgme.2011.07.014.
42. Massaccesi L, Burlina A, Baquero CJ, Goi G, Burlina AP, Tettamanti G. Whole-blood alpha-D-galactosidase A activity for the identifcation of Fabry's patients. Clin Biochem. 2011;44:916-921. doi: 10.1016/j. clinbiochem.2011.03.141.
43. Schiffmann R, Forni S, Swift C, Brignol N, Wu X, Lockhart DJ, et al. Risk of death in heart disease is associated with elevated urinary globotriaosylce-ramide. J Am Heart Assoc. 2014;3:e000394. doi: 10.1161/JAHA.113.000394.
44. Lenders M, Duning T, Schelleckes M, Schmitz B, Stander S, Rolfs A, et al. Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene. PLoS One. 2013;8:e55565. doi: 10.1371/journal.pone.0055565.
45. Filoni C, Caciotti A, Carraresi L, Cavicchi C, Parini R, Antuzzi D, et al. Functional studies of new GLA gene mutations leading to conforma-tional Fabry disease. Biochim Biophys Acta. 2010;1802:247-252. doi: 10.1016/j.bbadis.2009.11.003.
46. Niemann M, Rolfs A, Störk S, Bijnens B, Breunig F, Beer M, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defnes Fabry disease. Circ Cardiovasc Genet. 2014;7:8-16. doi: 10.1161/CIRCGENETICS.113.000249.
47. Froissart R, Piraud M, Maire I. [Contribution of genotyping in Fabry's disease]. Rev Med Interne. 2010;31(suppl 2):S275-S278. doi: 10.1016/S0248-8663(10)70027-8.
48. Gaspar P, Herrera J, Rodrigues D, Cerezo S, Delgado R, Andrade CF, et al. Frequency of Fabry disease in male and female haemodialysis patients in Spain. BMC Med Genet. 2010;11:19. doi: 10.1186/1471-2350-11-19.
49. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodefciency allele. Hum Mutat. 2003;22:486-492. doi: 10.1002/humu.10275.
50. Hoffmann B, Georg Koch H, Schweitzer-Krantz S, Wendel U, Mayatepek E. Defcient alpha-galactosidase A activity in plasma but no Fabry dis-ease-a pitfall in diagnosis. Clin Chem Lab Med. 2005;43:1276-1277. doi: 10.1515/CCLM.2005.219.
51. van der Tol L, Smid BE, Poorthuis BJ, Biegstraaten M, Deprez RH, Linthorst GE, et al. A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown signifcance. J Med Genet. 2014;51:1-9. doi: 10.1136/jmedgenet-2013-101857.
52. Lukas J, Giese AK, Markoff A, Grittner U, Kolodny E, Mascher H, et al. Functional characterisation of alpha-galactosidase a mutations as a basis for a new classifcation system in fabry disease. PLoS Genet. 2013;9:e1003632. doi: 10.1371/journal.pgen.1003632.
53. von Sarnowski, Putaala J, Grittner U, Gaertner B, Schminke U, Curtza S, et al. Lifestyle risk factors for ischemic stroke and transient isch-emic attack in young adults in the Stroke in Young Fabry Patients study. Stroke. 2013;44:119-125.
54. Barris-Oliveira AC, Müller KB, Turaça LT, Pesquero JB, Martins AM, D'Almeida V. Higher frequency of paraoxonase gene polymorphism and cardiovascular impairment among Brazilian Fabry Disease patients. Clin Biochem. 2012;45:1459-1462. doi: 10.1016/j.clinbiochem.2012.06.034.
55. Altarescu G, Haim S, Elstein D. Angiotensinogen promoter and angio-tensinogen II receptor type 1 gene polymorphisms and incidence of ischemic stroke and neurologic phenotype in Fabry disease. Biomarkers. 2013;18:595-600. doi: 10.3109/1354750X.2013.836244.
56. Kaneski CR, Moore DF, Ries M, Zirzow GC, Schiffmann R. Myeloperoxidase predicts risk of vasculopathic events in hemizgy-gous males with Fabry disease. Neurology. 2006;67:2045-2047. doi: 10.1212/01.wnl.0000247278.88077.09.
57. Kikumoto Y, Kai Y, Morinaga H, Iga-Murahashi M, Matsuyama M, Sasaki T, et al. Fabry disease exhibiting recurrent stroke and persistent infammation. Intern Med. 2010;49:2247-2252.
58. Demuth K, Germain DP. Endothelial markers and homocyste-ine in patients with classic Fabry disease. Acta Paediatr Suppl. 2002;91:57-61.
59. Fedi S, Gensini F, Gori AM, Abbate R, Borsini W. Homocysteine and tissue factor pathway inhibitor levels in patients with Fabry's disease. J Thromb Haemost. 2005;3:2117-2119. doi: 10.1111/j.1538-7836.2005.01470.x.
60. Tchan M, Sillence D. Fabry disease and Factor V Leiden: a potent vascular risk combination. Intern Med J. 2011;41:422-426. doi: 10.1111/j.1445-5994.2011.02483.x.
61. Niemann M, Weidemann F. A dangerous combination: Fabry disease and factor V Leiden. Intern Med J. 2012;42:1270-1271. doi: 10.1111/j.1445-5994.2012.02954.x.
62. Gessoni G, Valverde S, Canistro R, Manoni F. Factor V Leiden in Chioggia: a prevalence study in patients with venous thrombosis, their blood relatives and the general population. Blood Transfus. 2010;8:193-195. doi: 10.2450/2010.0157-09.
63. Mogi M, Horiuchi M. Clinical interaction between brain and kidney in small vessel disease. Cardiol Res Pract. 2011;2011:306189. doi: 10.4061/2011/306189.
64. Warnock DG, Ortiz A, Mauer M, Linthorst GE, Oliveira JP, Serra AL, et al; Fabry Registry. Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant. 2012;27:1042-1049. doi: 10.1093/ndt/gfr420.
65. Steinicke R, Gaertner B, Grittner U, Schmidt W, Dichgans M, Heuschmann PU, et al. Kidney function and white matter disease in young stroke patients: analysis of the stroke in young Fabry patients study population. Stroke. 2012;43:2382-2388. doi: 10.1161/STROKEAHA.111.645713.
66. Rost N, Metterville DR, Cloonan LK, Fitzpatrick KM, Germain D, Politei JM, et al. White matter hyperintensity volume assessment in patients with Fabry disease [abstract 198]. Mol Genet Metab. 2013;108(suppl):S80.
67. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifers on cerebral lesions in Fabry disease. Neurology. 2005;64:2148-2150. doi: 10.1212/01.WNL.0000166000.24321.4F.
68. Moore DF, Kaneski CR, Askari H, Schiffmann R. The cerebral vasculop-athy of Fabry disease. J Neurol Sci. 2007;257:258-263. doi: 10.1016/j. jns.2007.01.053.
69. Moore DF, Krokhin OV, Beavis RC, Ries M, Robinson C, Goldin E, et al. Proteomics of specifc treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities. Proc Natl Acad Sci USA. 2007;104:2873-2878. doi: 10.1073/pnas.0611315104.
70. Fellgiebel A, Keller I, Martus P, Ropele S, Yakushev I, Böttcher T, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis. 2011;31:294-299. doi: 10.1159/000322558.
71. Uçeyler N, Homola GA, Guerrero González H, Kramer D, Wanner C, Weidemann F, et al. Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease. PLoS One. 2014;9:e87054. doi: 10.1371/journal.pone.0087054.
72. Politei J, Schenone AB, Burlina A, Blanco M, Lescano S, Szlago M, et al. Vertebrobasilar dolichoectasia in Fabry Disease: the earliest marker of neurovascular involvement? J Inborn Errors Metab Screening. 2014;2:2326409814541246. doi:10.1177/2326409814541246.
73. Sodi A, Ioannidis AS, Mehta A, Davey C, Beck M, Pitz S. Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey. Br J Ophthalmol. 2007;91:210-214. doi: 10.1136/bjo.2006.100602.
74. Moore DF, Altarescu G, Barker WC, Patronas NJ, Herscovitch P, Schiffmann R. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull. 2003;62:231-240.
75. Burlina A, Manara R. Brain MRI in inherited metabolic diseases of adulthood. In: Hollak C, Lachmann R, Sedel F, eds. A Clinical Guide to Inherited Metabolic Diseases in Adults. Oxford, UK: Oxford University Press; 2015.
76. Kaye EM, Kolodny EH, Logigian EL, Ullman MD. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol. 1988;23:505-509. doi: 10.1002/ana.410230513.
77. deVeber GA, Schwarting GA, Kolodny EH, Kowall NW. Fabry disease: immunocytochemical characterization of neuronal involvement. Ann Neurol. 1992;31:409-415. doi: 10.1002/ana.410310410.
78. Crutchfeld KE, Patronas NJ, Dambrosia JM, Frei KP, Banerjee TK, Barton NW, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology. 1998;50:1746-1749.
79. Fellgiebel A, Müller MJ, Mazanek M, Baron K, Beck M, Stoeter P. White matter lesion severity in male and female patients with Fabry disease. Neurology. 2005;65:600-602. doi: 10.1212/01. wnl.0000173030.70057.eb.
80. Böttcher T, Rolfs A, Tanislav C, Bitsch A, Köhler W, Gaedeke J, et al. Fabry disease-underestimated in the differential diagnosis of multiple sclerosis? PLoS One. 2013;8:e71894. doi: 10.1371/journal. pone.0071894.
81. Paavilainen T, Lepomäki V, Saunavaara J, Borra R, Nuutila P, Kantola I, et al. Diffusion tensor imaging and brain volumetry in Fabry disease patients. Neuroradiology. 2013;55:551-558. doi: 10.1007/s00234-012-1131-8.
82. Matute C, Domercq M, Pérez-Samartín A, Ransom BR. Protecting white matter from stroke injury. Stroke. 2013;44:1204-1211. doi: 10.1161/STROKEAHA.112.658328.
83. Black S, Gao F, Bilbao J. Understanding white matter disease: imaging-pathological correlations in vascular cognitive impairment. Stroke. 2009;40(suppl 1):S48-S52. doi: 10.1161/STROKEAHA.108.537704.
84. Van Le Q, Isbell LA, Matsumoto J, Nguyen M, Hori E, Maior RS, et al. Pulvinar neurons reveal neurobiological evidence of past selection for rapid detection of snakes. Proc Natl Acad Sci USA. 2013;110:19000-19005. doi: 10.1073/pnas.1312648110.
85. Takanashi J, Barkovich AJ, Dillon WP, Sherr EH, Hart KA, Packman S. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol. 2003;24:916-921.
86. Moore DF, Ye F, Schiffmann R, Butman JA. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol. 2003;24:1096-1101.
87. Gavazzi C, Borsini W, Guerrini L, Della Nave R, Rocca MA, Tessa C, et al. Subcortical damage and cortical functional changes in men and women with Fabry disease: a multifaceted MR study. Radiology. 2006;241:492-500. doi: 10.1148/radiol.2412051122.
88. Burlina AP, Manara R, Caillaud C, Laissy JP, Severino M, Klein I, et al. The pulvinar sign: frequency and clinical correlations in Fabry disease. J Neurol. 2008;255:738-744. doi: 10.1007/s00415-008-0786-x.
89. Burlina AP, Politei J, Cinque S, Soliani A, Carlier RY, Germain DP, et al. The pulvinar sign in Fabry patients: the frst report in female patients. J Neurol. 2012;259:1227-1228. doi: 10.1007/s00415-011-6305-5.
90. Igarashi T, Sakuraba H, Suzuki Y. Activation of platelet function in Fabry's disease. Am J Hematol. 1986;22:63-67.
91. Tosoni A, Nebuloni M, Zerbi P, Vago L, Comotti C, Sessa A. Ultrastructural study of renal involvement in two females with Anderson-Fabry disease. Ultrastruct Pathol. 2005;29:203-207. doi: 10.1080/01913120590951202.
92. DeGraba T, Azhar S, Dignat-George F, Brown E, Boutière B, Altarescu G, et al. Profle of endothelial and leukocyte activation in Fabry patients. Ann Neurol. 2000;47:229-233.
93. Shen JS, Meng XL, Moore DF, Quirk JM, Shayman JA, Schiffmann R, et al. Globotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells. Mol Genet Metab. 2008;95:163-168. doi: 10.1016/j.ymgme.2008.06.016.
94. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and infammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21:20-27. doi: 10.1038/sj.jhh.1002101.
95. Shu L, Shayman JA. Caveolin-associated accumulation of globotriaosyl-ceramide in the vascular endothelium of alpha-galactosidase A null mice. J Biol Chem. 2007;282:20960-20967. doi: 10.1074/jbc.M702436200.
96. Park S, Kim JA, Joo KY, Choi S, Choi EN, Shin JA, et al. Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease. Cardiovasc Res. 2011;89:290-299. doi: 10.1093/cvr/cvq333.
97. Barbey F, Brakch N, Linhart A, Rosenblatt-Velin N, Jeanrenaud X, Qanadli S, et al. Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and gly-cosphingolipid deposition. Arterioscler Thromb Vasc Biol. 2006;26:839-844. doi: 10.1161/01.ATV.0000209649.60409.38.
98. Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, et al. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31:67-76. doi: 10.1093/eurheartj/ehp387.
99. Kalliokoski RJ, Kalliokoski KK, Penttinen M, Kantola I, Leino A, Viikari JS, et al. Structural and functional changes in peripheral vas-culature of Fabry patients. J Inherit Metab Dis. 2006;29:660-666. doi: 10.1007/s10545-006-0340-x.
100. Barbey F, Qanadli SD, Juli C, Brakch N, Palacek T, Rizzo E, et al. Aortic remodelling in Fabry disease. Eur Heart J. 2010;31:347-353. doi: 10.1093/eurheartj/ehp426.
101. Rombach SM, van den Bogaard B, de Groot E, Groener JE, Poorthuis BJ, Linthorst GE, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. Hypertension. 2012;60:998-1005. doi: 10.1161/HYPERTENSIONAHA.112.195685.
102. Chen KD, Li YS, Kim M, Li S, Yuan S, Chien S, et al. Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J Biol Chem. 1999;274:18393-18400.
103. Sho E, Sho M, Singh TM, Nanjo H, Komatsu M, Xu C, et al. Arterial enlargement in response to high fow requires early expression of matrix metalloproteinases to degrade extracellular matrix. Exp Mol Pathol. 2002;73:142-153.
104. Tronc F, Mallat Z, Lehoux S, Wassef M, Esposito B, Tedgui A. Role of matrix metalloproteinases in blood fow-induced arterial enlargement: interaction with NO. Arterioscler Thromb Vasc Biol. 2000;20:E120-E126.
105. Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med. 2006;259:381-392. doi: 10.1111/j.1365-2796.2006.01624.x.
106. Shah JS, Hughes DA, Tayebjee MH, MacFadyen RJ, Mehta AB, Elliott PM. Extracellular matrix turnover and disease severity in Anderson-Fabry disease. J Inherit Metab Dis. 2007;30:88-95. doi: 10.1007/s10545-006-0360-6.
107. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. Reduced cerebral blood fow velocity and impaired cerebral autoregula-tion in patients with Fabry disease. J Neurol. 2004;251:564-570. doi: 10.1007/s00415-004-0364-9.
108. Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, et al. Local and global cerebral blood fow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. J Neurochem. 2001;79:1217-1224.
109. Uçeyler N, He L, Kahn AK, Breunig F, Müllges W, Sommer C. Cerebral blood fow in patients with Fabry disease as measured by Doppler sonog-raphy is not different from that in healthy individuals and is unaffected by treatment. J Ultrasound Med. 2012;31:463-468.
110. Moore DF, Altarescu G, Ling GS, Jeffries N, Frei KP, Weibel T, et al. Elevated cerebral blood fow velocities in Fabry disease with reversal after enzyme replacement. Stroke. 2002;33:525-531.
111. Moore DF, Herscovitch P, Schiffmann R. Selective arterial distribution of cerebral hyperperfusion in Fabry disease. J Neuroimaging. 2001;11:303-307.
112. Stemper B, Hilz MJ. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggests sympathetic vasomotor dysfunction in Fabry disease. J Neurol. 2003;250:970-976. doi: 10.1007/s00415-003-1133-x.
113. Hilz MJ, Marthol H, Schwab S, Kolodny EH, Brys M, Stemper B. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. J Hypertens. 2010;28: 1438-1448. doi: 10.1097/HJH.0b013e328336a077.
114. Hilz MJ, Koehn J, Kolodny EH, Brys M, Moeller S, Stemper B. Metronomic breathing shows altered parasympathetic barorefex function in untreated Fabry patients and barorefex improvement after enzyme replacement therapy. J Hypertens. 2011;29:2387-2394. doi: 10.1097/HJH.0b013e32834c31db.
115. Torralba-Cabeza MÁ, Olivera S, Hughes DA, Pastores GM, Mateo RN, Pérez-Calvo JI. Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease. Mol Genet Metab. 2011;104:301-307. doi: 10.1016/j. ymgme.2011.06.021.
116. Waldek S, Feriozzi S. Fabry nephropathy: a review-how can we optimize the management of Fabry nephropathy? BMC Nephrol. 2014;15:72. doi: 10.1186/1471-2369-15-72.
117. Pereira EM, do Monte SJ, do Nascimento FF, de Castro JA, Sousa JL, Filho HC, et al. Lysosome-associated protein 1 (LAMP-1) and lyso-some-associated protein 2 (LAMP-2) in a larger family carrier of Fabry disease. Gene. 2014;536:118-122. doi: 10.1016/j.gene.2013.11.063.
118. Cigna D, D'Anna C, Zizzo C, Francofonte D, Sorrentino I, Colomba P, et al. Alteration of proteomic profles in PBMC isolated from patients with Fabry disease: preliminary fndings. Mol Biosyst. 2013;9:1162-1168. doi: 10.1039/c3mb25402j.
119. Ferraz MJ, Kallemeijn WW, Mirzaian M, Herrera Moro D, Marques A, Wisse P, et al. Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses. Biochim Biophys Acta. 2014;1841:811-825. doi: 10.1016/j.bbalip.2013.11.004.
120. Schiffmann R, Ries M, Blankenship D, Nicholls K, Mehta A, Clarke JT, et al. Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genet Med. 2013;15:983-989. doi: 10.1038/gim.2013.56.
121. Rombach SM, Dekker N, Bouwman MG, Linthorst GE, Zwinderman AH, Wijburg FA, et al. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim Biophys Acta. 2010;1802:741-748. doi: 10.1016/j. bbadis.2010.05.003.
122. Liu HC, Lin HY, Yang CF, Liao HC, Hsu TR, Lo CW, et al. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919GA). Orphanet J Rare Dis. 2014;9:111. doi: 10.1186/s13023-014-0111-y.
123. 3-related analogues in Fabry disease. Anal Chem. 2014;86:3476-3483. doi: 10.1021/ac404000d.
124. Shu L, Vivekanandan-Giri A, Pennathur S, Smid BE, Aerts JM, Hollak CE, et al. Establishing 3-nitrotyrosine as a biomarker for the vascu-lopathy of Fabry disease. Kidney Int. 2014;86:58-66. doi: 10.1038/ki.2013.520.
125. Segura T, Ayo-Martín O, Gómez-Fernandez I, Andrés C, Barba MA, Vivancos J. Cerebral hemodynamics and endothelial function in patients with Fabry disease. BMC Neurol. 2013;13:170. doi: 10.1186/1471-2377-13-170.
126. Fellgiebel A, Keller I, Marin D, Müller MJ, Schermuly I, Yakushev I, et al. Diagnostic utility of different MRI and MR angiography measures in Fabry disease. Neurology. 2009;72:63-68. doi: 10.1212/01. wnl.0000338566.54190.8a.
127. Fellgiebel A, Wolf DO, Kolodny E, Müller MJ. Hippocampal atrophy as a surrogate of neuronal involvement in Fabry disease. J Inherit Metab Dis. 2012;35:363-367. doi: 10.1007/s10545-011-9390-9.
128. Ortu E, Fancellu L, Sau GF, Falchi P, Traccis S, Pee GM, et al. Primary motor cortex hyperexcitability in Fabry's disease. Clin Neurophysiol. 2013;124:1381-1389.
129. Azevedo E, Mendes A, Seixas D, Santos R, Castro P, Ayres-Basto M, et al. Functional transcranial Doppler: presymptom-atic changes in Fabry disease. Eur Neurol. 2012;67:331-337. doi: 10.1159/000337906.
130. Ginsberg L, Manara R, Valentine AR, Kendall B, Burlina AP. Magnetic resonance imaging changes in Fabry disease. Acta Paediatr Suppl. 2006;95:57-62. doi: 10.1080/08035320600618908.
131. Albrecht J, Dellani PR, Müller MJ, Schermuly I, Beck M, Stoeter P, et al. Voxel based analyses of diffusion tensor imaging in Fabry disease. J Neurol Neurosurg Psychiatry. 2007;78:964-969. doi: 10.1136/jnnp.2006.112987.
132. Beare R, Srikanth V, Chen J, Phan TG, Stapleton J, Lipshut R, et al. Development and validation of morphological segmentation of age-related cerebral white matter hyperintensities. Neuroimage. 2009;47:199-203. doi: 10.1016/j.neuroimage.2009.03.055.
133. Callisaya ML, Beare R, Phan TG, Blizzard L, Thrift AG, Chen J, et al. Brain structural change and gait decline: a longitudinal population-based study. J Am Geriatr Soc. 2013;61:1074-1079. doi: 10.1111/jgs.12331.